Actively Recruiting
A Study to Evaluate the Safety and Effects of PF-08634404 Combined With Different Cancer Agents in People With Advanced Solid Tumors
Led by Pfizer · Updated on 2026-06-04
162
Participants Needed
45
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new medicine called PF-08634404 in combination with different cancer treatments for adults with advanced solid tumors, including advanced non-small cell lung cancer (NSCLC) that has spread and cannot be cured with standard treatments. The study aims to understand how PF-08634404 works with other cancer medicines, assess its safety, and observe any side effects that may occur. It also seeks to find out whether this combination can help treat solid tumors. Participants will receive PF-08634404 combined with either sigvotatug vedotin or other anticancer agents, given through intravenous (IV) infusion at clinical trial sites. The study has different parts: Part A tests PF-08634404 with sigvotatug vedotin, while Part B evaluates PF-08634404 with another anticancer agent. All treatments and monitoring happen at specialized clinics where medical staff oversee participants closely. During the study, researchers will monitor participants for side effects and treatment responses using measures such as adverse events, dose-limiting toxicities, and tumor response assessments according to RECIST v1.1 criteria for up to about five years. Blood tests will check drug levels and immune response. The study includes safety follow-up for 90 days after treatment and long-term observation to understand the effects over time.
CONDITIONS
Brief Title
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older
- Locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC) not eligible for surgery or curative chemoradiotherapy
- PD-L1 status available
- For Part B only: PD-L1 tumor proportion score (TPS) of 1% or higher
- Measurable disease based on RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Known gene alterations such as EGFR, ALK, ROS1, NTRK, BRAF, or MET
- History of another cancer within 3 years before study treatment or evidence of residual disease from prior cancer
- Active central nervous system (CNS) lesions including brainstem, meningeal, or spinal cord metastases or compression
- Leptomeningeal disease
- Active autoimmune diseases requiring systemic treatment within the past 2 years
- Previous systemic anti-tumor therapy for advanced or metastatic NSCLC
- Prior immunotherapy (except certain anti-PD-(L)1 as neoadjuvant or adjuvant), antibody-drug conjugates with MMAE payload, anti-angiogenic therapy, or radiotherapy to the lung within 6 months before starting study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days after the last study intervention; treatment duration varies by participant
Participants receive the study medicine PF-08634404 in combination with different anticancer agents as per protocol to treat advanced cancers.
Repeated visits for study treatment and monitoring during treatment period
Duration - Up to approximately 5 years
Participants are monitored for safety, treatment effects, and long-term outcomes after treatment ends.
Periodic visits for safety and efficacy assessments
Trial Site Locations
Total: 45 locations
1
Highlands Oncology Group, PA
Fayetteville, Arkansas, United States, 72703
Actively Recruiting
2
Highlands Oncology Group, PA
Rogers, Arkansas, United States, 72758
Actively Recruiting
3
Highlands Oncology Group, PA
Springdale, Arkansas, United States, 72762
Actively Recruiting
4
Providence Medical Foundation
Fullerton, California, United States, 92835
Actively Recruiting
5
Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center
Fullerton, California, United States, 92835
Actively Recruiting
6
Providence St. Jude Medical Center
Fullerton, California, United States, 92835
Actively Recruiting
7
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States, 80218
Actively Recruiting
8
BRCR Medical Center Inc.
Coral Springs, Florida, United States, 33065
Actively Recruiting
9
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States, 32763
Actively Recruiting
10
Orlando Health Ambulatory Care Center
Orlando, Florida, United States, 32806
Actively Recruiting
11
Orlando Health Cancer Institute
Orlando, Florida, United States, 32806
Actively Recruiting
12
Orlando Health Orlando Regional Medical Center
Orlando, Florida, United States, 32806
Actively Recruiting
13
BRCR Global - Tamarac
Tamarac, Florida, United States, 33321
Actively Recruiting
14
Montefiore Medical Center- Montefiore Medical Park
The Bronx, New York, United States, 10461
Actively Recruiting
15
Oncology Associates of Oregon, P.C.
Eugene, Oregon, United States, 97401
Actively Recruiting
16
Dallas Cancer Specialists
Garland, Texas, United States, 75042
Actively Recruiting
17
Southwest Oncology Associates
Houston, Texas, United States, 77030
Actively Recruiting
18
Lumi Research
Houston, Texas, United States, 77090
Actively Recruiting
19
US Oncology Investigational Products Center (IPC)
Irving, Texas, United States, 75063
Actively Recruiting
20
Voyage Clinical
Sugar Land, Texas, United States, 77479
Actively Recruiting
21
VCU Medical Center Gateway Building
Richmond, Virginia, United States, 23219
Actively Recruiting
22
Virginia Commonwealth University
Richmond, Virginia, United States, 23219
Actively Recruiting
23
VCU Health Stony Point
Richmond, Virginia, United States, 23235
Actively Recruiting
24
Massey Cancer Center Clinical & Translational Research Lab
Richmond, Virginia, United States, 23298
Actively Recruiting
25
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Actively Recruiting
26
VCU Health Community Memorial Hospital
South Hill, Virginia, United States, 23970
Actively Recruiting
27
VCU Health Tappahannock Hospital
Tappahannock, Virginia, United States, 22560
Actively Recruiting
28
Beijing Cancer hospital
Beijing, Beijing Municipality, China, 100142
Not Yet Recruiting
29
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Not Yet Recruiting
30
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China, 317000
Not Yet Recruiting
31
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)
Fano, Pesaro AND Urbino, Italy, 61032
Not Yet Recruiting
32
IRCCS Istituto Nazionale dei Tumori Regina Elena
Roma, ROME, Italy, 00144
Not Yet Recruiting
33
Ospedale Isola Tiberina - Gemelli Isola
Roma, ROME, Italy, 00186
Not Yet Recruiting
34
Kansai Medical University Hospital
Hirakata, Osaka, Japan, 573-1191
Actively Recruiting
35
Shizuoka Cancer Center
Nagaizumi-cho, Shizuoka, Japan, 411-8777
Actively Recruiting
36
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico, 00935
Actively Recruiting
37
BRCR Global Puerto Rico - Hato Rey
San Juan, Puerto Rico, 00917
Actively Recruiting
38
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalunya [cataluña], Spain, 08041
Not Yet Recruiting
39
Hospital Universitario San Cecilio
Granada, Spain, 18016
Not Yet Recruiting
40
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, 807
Actively Recruiting
41
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung City, Taiwan, 83301
Actively Recruiting
42
National Cheng Kung University Hospital
Tainan, Taiwan, 704
Actively Recruiting
43
National Taiwan University Hospital
Taipei, Taiwan, 100
Not Yet Recruiting
44
Mackay Memorial Hospital
Taipei, Taiwan, 10449
Actively Recruiting
45
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here